title: Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
abstract: One hundred de novo multiple myeloma patients with t(4;14) treated with double intensive therapy according to IFM99 protocols were retrospectively analyzed. The median overall survival (OS) and event-free survival (EFS) were 41.4 and 21 months, respectively, as compared to 65 and 37 for patients included in the IFM99 trials without t(4;14) (P<10(-7)). We identified a subgroup of patients presenting at diagnosis with both low beta(2)-microglobulin <4 mg/l and high hemoglobin (Hb) >/=10 g/l (46% of the cases) with a median OS of 54.6 months and a median EFS of 26 months, respectively, which benefits from high-dose therapy (HDT); conversely patients with one or both adverse prognostic factor (high beta(2)-microglobulin and/or low Hb) had a poor outcome. The achievement of either complete response or very good partial response after HDT was also a powerful independent prognostic factor for both OS and EFS.
authors.affiliation: Hematology Department, University Hospital, Nantes, France.
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: F
authors.initials: F
authors.lastname: Garban
authors.forename: C
authors.initials: C
authors.lastname: Hulin
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: C
authors.initials: C
authors.lastname: Doyen
authors.forename: S
authors.initials: S
authors.lastname: Leyvraz
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.forename: M
authors.initials: M
authors.lastname: Wetterwald
authors.forename: C
authors.initials: C
authors.lastname: Mathiot
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: C
authors.initials: C
authors.lastname: Berthou
authors.forename: L
authors.initials: L
authors.lastname: Benboubker
authors.forename: L
authors.initials: L
authors.lastname: Garderet
authors.forename: C
authors.initials: C
authors.lastname: Chaleteix
authors.forename: C
authors.initials: C
authors.lastname: Traullé
authors.forename: J G
authors.initials: JG
authors.lastname: Fuzibet
authors.forename: J
authors.initials: J
authors.lastname: Jaubert
authors.forename: T
authors.initials: T
authors.lastname: Lamy
authors.forename: P
authors.initials: P
authors.lastname: Casassus
authors.forename: M
authors.initials: M
authors.lastname: Dib
authors.forename: B
authors.initials: B
authors.lastname: Kolb
authors.forename: V
authors.initials: V
authors.lastname: Dorvaux
authors.forename: B
authors.initials: B
authors.lastname: Grosbois
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: H
authors.initials: H
authors.lastname: Avet-Loiseau
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002883:Chromosomes, Human, Pair 14; D002894:Chromosomes, Human, Pair 4; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018740:Genetic Heterogeneity; D006454:Hemoglobins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D014178:Translocation, Genetic; D014750:Vincristine / Q000008:administration & dosage; D001613:beta 2-Microglobulin / Q000097:blood
chemical_list: D006454:Hemoglobins; D001613:beta 2-Microglobulin; D003561:Cytarabine; D014750:Vincristine; D003907:Dexamethasone